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Retinopathy of prematurity (ROP) is a vasoproliferative disorder affecting the
retinas of premature infants. The screening, treatment, and pathophysiologic understanding of ROP have dramatically evolved over the past four decades. Two landmark studies, Cryotherapy for ROP (CRYO-ROP)1 in 1988 and Early Treatment for
ROP (ETROP)2 in 2004 have served as the stepping stones for establishing treatment guidelines with respect to threshold and prethreshold type 1 ROP.
Most recently, however, intravitreal anti‒vascular endothelial growth factor (antiVEGF) agents for ROP have received much attention in the medical community as a
potential alternative. Reported advantages of anti-VEGF pharmacotherapy over laser
photocoagulation include decreased treatment time with less stress on the neonate,
swift resolution of plus disease with prompt regression of ROP, potential of further
retinal vascular development with no ablation of the peripheral avascular retina, lower
risk of myopia, and improved treatment outcomes for zone I ROP or AP-ROP.3–5 AntiVEGF may also be the only treatment option in cases of media opacity or vitreous
hemorrhage when an insufﬁcient view is present for laser photocoagulation.
One of the largest anti-VEGF studies in ROP to date, the BEAT-ROP (Efﬁcacy of
Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity) trial,5 found that
bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) can halt
the progression of severe ROP, revert pathologic angiogenic changes, and induce the
progression of physiologic intraretinal vasculature. Of note, BEAT-ROP was the ﬁrst
prospective study to investigate anti-VEGF use for ROP at time when the preponderance of literature was in the form of retrospective case reports and series. Although
initial studies on anti-VEGF therapy for ROP have focused on bevacizumab, recent
studies have proposed the use of ranibizumab (Lucentis; Genentech Inc, San Francisco,
25

submit your manuscript | www.dovepress.com

Eye and Brain 2019:11 25–35

DovePress

© 2019 Patel and Klufas. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing
the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://doi.org/10.2147/EB.S189684

Powered by TCPDF (www.tcpdf.org)

Abstract: Retinopathy of prematurity (ROP) is a leading and preventable cause of childhood
blindness worldwide. Although laser photocoagulation remains the gold standard for treatment,
the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP,
particularly posterior zone I disease, is increasing. Although initial studies on anti-VEGF therapy
for ROP have focused on bevacizumab, recent studies have proposed that ranibizumab may be a
safer and more effective alternative for use in this population. This review updates recent
evidence regarding the use of ranibizumab in the management of ROP.
Keywords: retinopathy of prematurity, ranibizumab, bevacizumab, Lucentis, Avastin,
vascular endothelial growth factor, RAINBOW, BEAT-ROP, anti-VEGF
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CA/Novartis Ophthalmics, Basel, Switzerland) for the treatment of ROP. In this article, we review the current evidence
of ranibizumab for the management of ROP.
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Molecular structure and function
Ranibizumab is a recombinant humanized monoclonal
antibody fragment designed to bind and inhibit all biologically active isoforms of human VEGF.6 The VEGF
family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, and placental growth factor, among which the
most important member is VEGF-A.7 VEGF-A is a
dimeric, disulﬁde-bound glycoprotein that is speciﬁcally
activated on endothelial cells and plays a key role in
various processes such as inducing angiogenesis, accelerating the endothelial cell growth, promoting cell migration, and inhibiting apoptosis and tumor growth. At least
six VEGF-A isoforms including VEGF121, VEGF145,
VEGF165, VEGF183, VEGF189, and VEGF206 are produced
by alternative splicing of the VEGF-A gene.8
Like ranibizumab, bevacizumab is another monoclonal
antibody that binds and inhibits all isoforms of VEGF with
a lower afﬁnity (Table 1). Ranibizumab and bevacizumab
locate in the receptor-binding region of VEGF and both
antibodies target VEGF in a similar way. However, bevacizumab (149 kDa) and ranibizumab (48.39 kDa) have
different molecular weights, mainly because ranibizumab
does not contain a fragment crystallizable (Fc) region.
Figure 1 shows the molecular structure of ranibizumab
that includes a heavy chain (antigen-binding fragment)
and light chain. Furthermore, bevacizumab is produced
in a eukaryotic cell line and is N-glycosylated in its Fc
region, while ranibizumab is produced in prokaryotic E.
coli, and therefore it does not carry any glycosylation sites.
Additionally, though both bevacizumab and ranibizumab
are off-label treatments for ROP, for other ocular conditions, bevacizumab is only FDA approved for intravenous
administration, whereas ranibizumab is approved and
Table 1 Differences in structure and function between ranibizumab and bevacizumab
Ranibizumab

Bevacizumab

Molecule

Fab fragment

Full length antibody

Glycosylation

No

Yes

Fc
Molecular weight

No
48.39 kDa

Yes
139 kDa

Half-life

3 days

17–21 days

26
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Figure 1 Molecular structure of ranibizumab. The heavy chain of the antigenbinding fragment is in dark blue and the light chain is in light blue. Permission to
use this ﬁgure was obtained from Genetech.

formulated for intraocular administration. In clinical practice in the United States, bevacizumab is compounded for
intraocular use from the intravenous formulation by compounding pharmacies.
In animal models assessing the vitreous pharmacokinetics of anti-VEGF medications, the vitreous half-life of
0.5-mg intravitreal ranibizumab was 2.88 days, whereas
the half-life of 1.25-mg intravitreal bevacizumab was 4.32
days.9 Furthermore, no ranibizumab was detected in the
serum or the fellow uninjected eye, but bevacizumab was
detected in the serum and fellow uninjected eye.9 Systemic
pharmacokinetics that reported that bevacizumab has a
longer half-life of 17–21 days compared to 3 days for
ranibizumab.10 These ﬁndings suggest that bevacizumab
may potentially lead to more systemic absorption.

Systemic safety data
One of the most important barriers to widespread antiVEGF use in ROP is the lack of certainty regarding the
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systemic long-term effects of intravitreal anti-VEGF therapy in neonates. Nearly 66% of pediatrics and retina
specialist in a recent survey reported a lack of certainty
in the systemic effects of intravitreal anti-VEGF agents to
treat ROP.11 The pharmacokinetic differences between
bevacizumab and ranibizumab may be particularly important for safety considerations in premature infants undergoing organogenesis. VEGF is important to kidney, brain,
and lung development, as well as to retinal and neuronal
health.12 Inhibiting VEGF thus raises concerns about
developing organs in the premature infant.
In adults with exudative age-related macular degeneration,
Carneiro et al13 showed bevacizumab signiﬁcantly reduced
VEGF plasma levels until 28 days after intravitreal injection,
whereas ranibizumab did not achieve signiﬁcant plasma
VEGF reduction at the same time-point. Sato et al14 showed
VEGF level signiﬁcantly decreased 1 week after intravitreal
bevacizumab in ROP infants, and the VEGF level had a signiﬁcant negative correlation to serum bevacizumab level.
Their ﬁndings suggest that bevacizumab escapes from the
vitreous into the systemic circulation and reduces the serum
VEGF concentrations in ROP infants after the intravitreal
bevacizumab. Two additional studies found that intravitreal
bevacizumab results in low VEGF serum levels for at least 8
weeks15 and up to 12 weeks after the treatment.16 In contrast,
when using ranibizumab, one study showed that intravitreal
ranibizumab can lower serum levels of VEGF by 1 day after
treatment, but this effect is short lived and serum VEGF levels
recover to baseline within 1 week of treatment.17 Furthermore,
in the CARE-ROP study (Comparing Alternative
Ranibizumab Dosages for Safety and Efﬁcacy in Retinopathy
of Prematurity), plasma VEGF levels were not altered in 9
infants receiving 0.12 mg or in 7 infants receiving 0.20 mg of
ranibizumab.18 However, Wong et al,19 in a case series,
reported paradoxical improvement in both eyes of a patient
undergoing unilateral intravitreal ranibizumab injection, which
supports the notion that decreased systemic VEGF levels from
unilateral injections may have clinically relevant effects.
Whether there are neurodevelopmental complications
related to anti-VEGF treatment in neonates remains to be
seen. No level I studies have addressed the long-term ocular,
visual, systemic, or neurodevelopmental effects of intraocular anti-VEGF treatment. This is partly due to the need for a
very large patient population and very long follow-up for
such a study to be powered correctly to sort out confounding
variables given that treatment-requiring ROP is known to be
associated with comorbidities and poor neurodevelopmental
outcomes. Despite these limitations, the current evidence is
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variable regarding neurodevelopmental outcomes in infants
with ROP receiving anti-VEGF therapy. Morin et al20 noted
that, in 125 infants treated for ROP, the odds of having a
severe neurodevelopmental disability (severe cerebral palsy,
hearing aids, or bilateral blindness) were 3.1 times higher
with bevacizumab versus laser treatment. However, the
authors acknowledged the study was limited by being retrospective, nonrandomized and because infants treated with
bevacizumab tended to be sicker with more severe health
problems. In contrast, Araz-Ersan et al21 evaluated series of
13 infants treated with combination intravitreal bevacizumab
and laser therapy for ROP, compared with an age-matched
control group of children who had received laser treatment
for ROP, and found no difference in the mean cognitive,
language, or motor scores based on the Bayley Scales of
Infant Development (BSID) test. Lien et al22 reported no
difference in mental or psychomotor impairment when comparing bevacizumab monotherapy to laser monotherapy, but
patients with combination therapy of laser and bevacizumab
had higher incidence of mental or psychomotor impairment.

Current literature on ranibizumab
for ROP
A 2017 report by the American Academy of Ophthalmology
on the use of anti-VEGFs for the primary treatment of ROP
noted no level I evidence on the subject.3 A recent Cochrane
review in 2018 concluded that there was insufﬁcient evidence to provide a strong conclusion for the routine use of
intravitreal anti-VEGFs in clinical practice.23 To date, eight
head-to-head studies19,24–31 have been published comparing
intravitreal ranibizumab to intravitreal bevacizumab and/or
conventional laser photocoagulation for ROP and three retrospective studies32–34 with at least 100 eyes have been published on outcomes of infants treated intravitreal ranibizumab
monotherapy (Table 2).
In 2017, Zhang et al24 reported outcomes of a prospective randomized clinical trial for 50 infants who had bilateral type 1 ROP in zone II who were randomized to
receive either intravitreal ranibizumab (0.3 mg in 0.03
mL) or diode (810 nm) laser photocoagulation. No information was available on randomization administration
and/or masking. The main outcomes assessed were regression of ROP and plus disease, recurrence requiring treatment, and complications. In the ranibizumab group, 26 of
50 (50%) eyes demonstrated recurrence and underwent
laser photocoagulation with a mean interval to retreatment
of 12.6±7.9 weeks. In the laser group, 2 of 40 (4%) eyes
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review

Retrospective chart

review

Retrospective chart
review

Retrospective chart

review

Ophthalmology, 201634

Erol et al, Arquivos

Brasileiros de
Oftalmologia, 201528

Chen et al, Retina,
201527

Alyamac et al,

Ophthalmologica,

Gunay et al, Current
Eye Research, 201725

Eye Research, 2017
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Kabatas et al, Current

series

Retrospective
interventional case

review

Retrospective chart

Retrospective chart

Lin et al, Clinical

201626

Retrospective chart
review

Design

Wong et al, Retina,
201519

Study

● Bevacizumab 0.625 mg (21 eyes)
● Ranibizumab 0.25 mg (15 eyes)
● Bevacizumab 0.625 mg (41 eyes)
● Ranibizumab 0.25 mg (31 eyes)

● Bevacizumab 0.625 mg (44 eyes)
● Ranibizumab 0.25 mg (46 eyes)

● 20 infants (36 eyes)
● Type 1 ROP
● Duration: 20 months
● 37 infants (72 eyes)
● Type 1 ROP
● Duration: 1 year
● 45 infants (90 eyes)
● Type I ROP with zone I or

● Bevacizumab 0.625 mg (24 eyes)
● Ranibizumab 0.25 mg (12 eyes)
● Laser (72 eyes)
● Bevacizumab 0.625 mg (107 eyes)
● Ranibizumab 0.25 mg (44 eyes)
● Laser (113 eyes)

● 54 infants (108 eyes)
● Type 1 ROP
● Duration: 18 months
● 134 infants (264 eyes)
● Type 1 ROP and AP-ROP
● Duration: 17.6–23 months

● Duration: 6–12 months

posterior zone II disease

● Bevacizumab 0.625 mg (25 eyes)
● Ranibizumab 0.25 mg (15 eyes)

● Bevacizumab 0.625 mg (4 eyes)
● Ranibizumab 0.25 mg (6 eyes)

Intervention

● 21 infants (40 eyes)
● Type 1 ROP
● Duration: 1 year

● Duration: 9–16 months

ROP

● 6 infants (10 eyes)
● Zone I or posterior zone II

Participants

Table 2 Comparative studies of ranibizumab for retinopathy of prematurity

(13.6%) ranibizumab, 0 (0%) laser.

(Continued)

● Recurrence requiring further treatment: 3 (5.5%) bevacizumab, 3

14±2.7 weeks with bevacizumab

● Mean time to recurrence: 8.8±1.5 weeks with ranibizumab compared to

(5.5%) infants treated with bevacizumab

● Recurrence rate: 11/22 (50%) infants treated with ranibizumab vs 3/55

bevacizumab and ranibizumab

● Complete resolution of neovascularization after single injection with

● No difference in refractive error between treatment groups

PMA vs 2/24 (8.3%) eyes treated with bevacizumab at 52 weeks PMA.

● Recurrence rate: 2/12 (16%) eyes treated with ranibizumab at 48 weeks

ranibizumab

● Recurrence requiring further treatment: 2 (33%) bevacizumab, 2 (14%)

val of 7.8 weeks vs 6/22 (10%) infants treated with bevacizumab at
interval of 8.5 weeks

● Recurrence rate: 14/23 (61%) infants treated with ranibizumab at inter-

and ranibizumab

● No difference in time to mean vascularization between bevacizumab

ranibizumab

● No difference in mean refractive error between bevacizumab or

bevacizumab

● No recurrence of ROP in eyes treated with ranibizumab or

(10%) eyes treated with bevacizumab

● Recurrence rate: 4/15 (27%) eyes treated with ranibizumab vs 2/21

● No difference in rates of axial length or spherical equivalent

vs 7/15 (47%) eyes treated with bevacizumab

● Complete vascularization in 15/25 (60%) eyes treated with ranibizumab

● No recurrence of ROP in eyes treated with bevacizumab

of 5.9 weeks.

● Recurrence rate: 5/6 (83%) eyes treated with ranibizumab at an interval

Outcomes
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Retrospective chart

review

Retrospective chart

review

Retrospective chart

Tong et al, BMC

Ophthalmology, 201834

Feng et al,

Ophthalmology, 201733

Huang et al,

Prospective, non-

randomized –
Intervention case series

Castellanos et al, Br J

Ophthalmology, 201331

Ophthalmology, 2017

review

Randomized Clinical
trial

Zhang et al, Retina,
201724

32

Design

Study

Table 2 (Continued).

● 3 infants (6 eyes)
● Type 1 ROP
● Duration: 3 years

● 145 infants (283 eyes)
● Type I ROP

type 1 prethreshold ROP

● 331 infants (629 eyes)
● APROP, type 1 ROP, and

● 83 infants (160 eyes)
● APROP

● Duration: 6 months

● Ranibizumab 0.25 mg

● Ranibizumab 0.25 mg

● Ranibizumab 0.25 mg

● Ranibizumab 0.3 mg (160 eyes)

● Ranibizumab 0.3 mg (50 eyes)
● Laser (50 eyes)

● 100 eyes
● Type 1 ROP, zone II, stage 2
or 3+

Intervention

Participants

● Complete resolution of neovascularization after single injection
● None developed unfavorable structural outcomes

● Recurrence rate: 127/266 (45%) eyes that had initial response
● Mean time to recurrence: 8.3±2.7 weeks

● Recurrence rate: 245/629 (39%) eyes.
● Mean time to recurrence: 8.57±3.73 weeks (range: 4–29 weeks)

● Recurrence rate: 82/160 (51%) eyes.
● Progression to retinal detachment in 35/160 (22%) eyes

(4%) eyes treated with laser

● Recurrence rate: 26/50 (50%) eyes treated with ranibizumab vs 2/50

Outcomes
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did not show an initial response and subsequently received
ranibizumab injections 1 week after the laser treatment.
In 2017, Gunay et al25 reported outcomes of a retrospective review of 134 infants (264 eyes) with type 1 ROP or
aggressive posterior ROP at 2 large referral centers in Turkey
who received either intravitreal bevacizumab (55 infants;
dose, 0.625 mg), intravitreal ranibizumab (22 infants; dose,
0.25 mg), or diode laser photocoagulation (57 infants). Main
outcome measures assessed were regression of ROP, recurrence proﬁle, complications after each treatment modality,
and indications for retreatment. All eyes showed an initial
response to treatment, but recurrence of ROP was seen in 3 of
55 infants (5.5%) treated with intravitreal bevacizumab, 11 of
22 (50%) infants treated with intravitreal ranibizumab, and 1
of 57 infants (1.7%) treated with laser photocoagulation. All
infants with recurrence in the bevacizumab group required
bilateral retreatment, but only 3 of the 11 (3%) with recurrence in the ranibizumab group required bilateral retreatment. At the last follow-up, the prevalence of emmetropia
was signiﬁcantly higher in the groups that received antiVEGF therapy compared with the laser-treated group
(50.9% of the bevacizumab group, 45.5% of the ranibizumab
group, and 16.3% of the laser group).
In 2016, Alyamac et al26 reported outcomes of a retrospective review of 45 infants (90 eyes) with type 1 ROP in
zone I or posterior zone II who received either intravitreal
bevacizumab (44 eyes; dose, 0.625 mg) or intravitreal
ranibizumab (46 eyes; dose, 0.25 mg). Main outcome
measures were rates of retinal vascularization. The mean
time to complete vascularization was 55.93±4.13 weeks
PMA in the bevacizumab group and 56.30±4.30 weeks
PMA in ranibizumab group. Recurrence was seen in 14
of 23 (61%) infants treated with ranibizumab and 6 of 22
(10%) infants treated with bevacizumab. Two of 6 (33%)
infants with recurrence in the bevacizumab group required
diode laser photocoagulation as additional treatment at 43
weeks PMA, whereas 2 of 14 (14%) infants with recurrence in the ranibizumab group required diode laser photocoagulation as additional treatment at 42.5 weeks PMA.
In 2015, Chen et al27 reported outcomes of a retrospective review of 37 infants (72 eyes) with type 1 ROP
who received either intravitreal bevacizumab (41 eyes;
dose, 0.625 mg) or intravitreal ranibizumab (31 eyes;
dose, 0.25 mg). Main outcome measures assessed were
recurrence of ROP and refractive errors at a corrected
age of 1 year. No recurrence of ROP occurred in either
group if the patients initially responded to either bevacizumab or ranibizumab. All but one eye in the bevacizumab

30
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group had retinal neovascularization and plus disease
regression after anti-VEGF treatment that required diode
laser photocoagulation. There was no difference in mean
refractive error between bevacizumab or ranibizumab.
However, there were 6 of 41 eyes (14.6%) in the bevacizumab group with high myopia (spherical equivalent ≤-5.0
diopters) compared to 0 of 31 eyes (0%) in the ranibizumab group.
In 2015, Erol et al28 reported outcomes of a retrospective review of 20 infants (36 eyes) with type 1 ROP who
received either intravitreal bevacizumab (21 eyes; dose,
0.625 mg) or intravitreal ranibizumab (15 eyes; dose, 0.25
mg). Recurrence was seen in 4 of 15 (27%) eyes treated
with ranibizumab and 2 of 21 (10%) eyes treated with
bevacizumab.
In 2017, Kabatas et al29 reported outcomes of a retrospective review of 54 infants (108 eyes) with type 1 ROP
who received intravitreal bevacizumab (24 eyes; dose,
0.625 mg), intravitreal ranibizumab (12 eyes; dose, 0.25
mg), or diode photocoagulation (72 eyes). Main outcome
measures assessed were recurrence of ROP, time to total
retinal vascularization, and refractive errors. Recurrence
was seen in 2 of 12 (16%) eyes treated with ranibizumab
and 2 of 24 (8.3%) eyes treated with bevacizumab. There
was no difference in refractive error among ranibizumab,
bevacizumab, and laser photocoagulation groups. The
mean time to complete vascularization in the bevacizumab
group was 73±10.1 weeks of PMA and 61.8±6.6 weeks of
PMA in the ranibizumab group.
In 2016, Lin et al30 reported outcomes of a retrospective review of 21 infants (40 eyes) with type 1 ROP who
received either intravitreal bevacizumab (25 eyes; dose,
0.625 mg) or intravitreal ranibizumab (15 eyes; dose, 0.25
mg). Main outcome measures were refractive status
including axial length and refraction at a corrected age of
1 year. Complete vascularization was noted in 15 of 25
(60%) eyes treated with ranibizumab and 7 of 15 (47%)
eyes treated with bevacizumab. There were no differences
in the rates of axial length or spherical equivalent between
ranibizumab and bevacizumab treatment groups.
In 2015, Wong et al19 reported outcomes of a retrospective review of 6 infants (10 eyes) with zone I or
posterior zone II ROP who received either intravitreal
bevacizumab (4 eyes; dose, 0.625 mg) or intravitreal ranibizumab (6 eyes; dose, 0.25 mg). Recurrence was seen in
5 of 6 (83%) eyes treated with ranibizumab on average 5.9
weeks after treatment. No recurrence was detected in the
four eyes treated with bevacizumab. One infant who
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received an unilateral injection of ranibizumab demonstrated bilateral regression of ROP.
In 2013, Castellanos et al31 reported outcomes of a
retrospective review of 3 infants (6 eyes) with type 1
ROP treated with intravitreal ranibizumab (0.25 mg) and
noted complete resolution of neovascularization after single injection. Three year follow-up showed no evidence of
recurrence or unfavorable structural outcomes.
In 2018, Tong et al34 reported outcomes of a retrospective review of 83 infants (160 eyes) with aggressive posterior ROP (APROP) treated with intravitreal ranibizumab
(0.25 mg). They noted that 35 of 160 (22%) eyes progressed
to retinal detachment and reported older postmenstrual age
and low neutrophil count as independent risk factors for
retinal detachment in APROP on multivariate analysis.
Recurrence requiring retreatment occurred in 82 of 160
(51%) eyes at a mean interval of 7.5±6.9 weeks after the
ﬁrst intravitreal ranibizumab treatment.
In 2017, Feng et al33 reported outcomes of a retrospective review of 331 infants (629 eyes) with APROP
(105 eyes), type 1 ROP (411 eyes), and type 1 prethreshold ROP (113 eyes) treated with intravitreal ranibizumab
(0.25 mg). Recurrence was seen in 70 of 105 (67%) eyes
with APROP, 157 of 411 (38%) eyes with type 1 ROP, and
18 of 113 (16%) eyes with prethreshold ROP. Mean time
to recurrence was 8.57±3.73 weeks (range: 4–29 weeks)
after treatment. The rate of recurrence was signiﬁcantly
higher in patients with zone I ROP (61%, 101 of 164 eyes)
than in zone II ROP (31%, 144 of 465 eyes). In patients
with recurrence, additional treatments included a second
intravitreal ranibizumab injection (92 eyes, 38%), supplemental diode photocoagulation (146 eyes, 60%), external
scleral buckle (2 eyes, 0.8%), and vitrectomy (5 eyes, 2%).
In 2017, Huang et al32 reported outcomes of a retrospective review of 145 infants (283 eyes) with type 1 ROP
who were treated with intravitreal ranibizumab (0.25 mg).
All eyes were classiﬁed into 2 groups: positive response
(regression of plus disease after injection, and/or retinal
vessels continued to develop into the peripheral area) and
negative/no response (deﬁned as ROP worsened after injection and developed into Stage 4A, 4B, or 5, or plus disease
and ridge did not show any change 1 week after injection).
A total of 266 of 283 (94%) eyes had a positive response
after intravitreal ranibizumab, and of them, 127 eyes (45%)
had initial regression with subsequent recurrence. The
recurrence rate was 47% in APROP, 58% in zone I, and
35% in zone II. The time between recurrence and initial
treatment was 8.3±2.7 weeks (range 2.3–15.4 weeks).
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Optimal dose of ranibizumab
Ranibizumab is commercially available in a vial and preﬁlled syringe form in two concentrations: 0.5 mg/0.05 mL
and 0.3 mg/0.05 mL. To date, large multicenter trials
found that the 0.5 mg dose was effective to treat agerelated macular degeneration, whereas the 0.3 mg dose
was equally efﬁcacious to treat diabetic macular edema
and diabetic retinopathy.35,36 The ﬁndings and variable
dosing intervals in the adult population support the premise that the dose of anti-VEGF drug may be disease
speciﬁc or patient speciﬁc. Retinal neovascularization
appears to be extremely sensitive to anti-VEGF therapy,
and potentially lower anti-VEGF doses may be effective
for ROP. However, the optimal dosages for both ranibizumab and bevacizumab remain unknown and controversial.
A dose that results in effective regression of ROP while
minimizing systemic penetration would be ideal due to
uncertainties regarding how these drugs affect premature
infants during neurodevelopmental growth.
The BEAT-ROP study demonstrated that 50% of the
adult anti-VEGF dose of bevacizumab is effective in halting ROP progression in the large majority of infants.5
Therefore, in the literature, the majority of ROP cases
treated with intravitreal ranibizumab use 50% (0.25 mg)
of the adult dose (range, 0.137–0.3 mg24). However, the
best possible dose is unknown, and it is unclear if even
lower doses of ranibizumab could be used with similar
effectiveness. The neonate eye is estimated to be less than
one-third the normal volume of an adult eye and, in
particular, the vitreous volume comprises only 20% of an
adult eye, which suggests that lower doses of anti-VEGF
may be more appropriate.38,39
In the multicenter randomized CARE-ROP study,
Stahl et al18 compared 2 doses of ranibizumab (0.12
mg and 0.20 mg) in infants with bilateral ROP and
assessed the number of infants who required rescue
therapy at 24 weeks. A total of 14 of 16 (88%) infants
achieved control of ROP without the need for rescue
therapy. Four infants (2 in each dose group) showed
recurrence of ROP and required retreatment with ranibizumab. Another study of 24 eyes with type 1 prethreshold ROP who received 0.1 mg of intravitreal
ranibizumab showed regression of disease in all cases
without any recurrence of disease or need for treatment
at 54 weeks post-menstrual age.37 These ﬁndings coincide with dose de-escalation studies of bevacizumab for
ROP, which found that dosing between 2.5% and 20%
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of the adult dose of bevacizumab may be effective in
controlling acute ROP though these dose levels may
lead to higher rates of recurrence.40,41
Effective dosing of ranibizumab may not only be
related to the total dose of medication administered but
also the timing of administration during the ROP disease
course. The optimal window for treatment with anti-VEGF
therapy is at the ﬁrst sign of plus disease or neovascularization but before the formation of extensive ﬁbrovascular
membranes. When administered in late stage 4 or 5 disease, ranibizumab may cause contraction of the ﬁbrovascular membranes and posterior hyaloid, thereby worsening
tractional retinal detachment.42 These changes may be
analogous to the “crunch” phenomenon observed in
patients with proliferative diabetic retinopathy in which
anti-VEGF therapy may worsen traction on the retina.43

Risk of recurrence of ROP treated
with ranibizumab
The rates and timing of ROP recurrence are variable among
study populations. As noted in Table 2, infants receiving
intravitreal ranibizumab had a mean (range) rate of ROP
recurrence of 41.1% (range, 0% to 83%). The wide discrepancies in ROP recurrence may be due to the differences in
the clinical deﬁnition of recurrence. In the studies examined,
recurrence was variably deﬁned as the reappearance of neovascularization, recurrent plus disease, extraretinal ﬁbrovascular proliferation, appearance of a ridge, or progression of
disease despite prior treatment. Additionally, dosing, treatment, zones, stages, and duration of follow-up vary, making
direct comparison between series difﬁcult. Furthermore,

recurrences may also occur with laser monotherapy as
ETROP reported unfavorable structural outcomes in 9% of
infants undergoing early treatment.2
In comparison with intravitreal bevacizumab and conventional laser ablative therapy, recurrence after intravitreal ranibizumab has been observed more frequently than
either intravitreal bevacizumab or laser monotherapy
(Figure 2). Because ranibizumab is an antibody fragment
with a shorter half-life, it is possible that the rate of
recurrence after initial injection may be higher in eyes
treated with ranibizumab because it is more rapidly cleared
from the eye compared to bevacizumab.10 Gunay et al25
found a higher rate of ROP recurrence in eyes treated with
ranibizumab (50%) compared with bevacizumab (5.5%),
but noted no difference in retreatment rates. At 1 year of
age, Chen et al27 reported that in a series of 72 eyes treated
with intravitreal bevacizumab (41 eyes) or ranibizumab
(31 eyes) there was no recurrence of ROP in either group
when there was an initial response to treatment.
Most published studies do not stratify risk of ROP recurrence based on the initial classiﬁcation of ROP disease.
However, Feng et al33 speciﬁcally reported rates of ROP
recurrence after intravitreal ranibizumab based on initial
ROP classiﬁcation and found that more aggressive forms of
ROP at initial treatment were signiﬁcantly correlated with
ROP recurrence. Based on ROP classiﬁcation, recurrence
was seen in 70 of 105 (67%) eyes with APROP, 157 of 411
(38%) eyes with type 1 ROP, and 18 of 113 (16%) eyes with
prethreshold ROP. Higher rates of recurrence in eyes with
APROP have previously been noted in patients receiving
either intravitreal ranibizumab34 or bevacizumab44 with low

Rates of ROP recurrence after treatment with intravitreal
ranibizumab versus bevacizumab
Ranibizumab

Kabatas et al

Bevacizumab
Erol et al
Gunay et al
Alymac et al
Wong et al
0

10

20

30

40

50

60

70

80

90

100

Rate of recurrence (%)
Figure 2 Rates of retinopathy of prematurity recurrence after treatment with intravitreal ranibizumab versus bevacizumab. Among the different studies, rates of recurrence
in patients receiving intravitreal ranibizumab (black) ranged from 16% to 83%, whereas rates of recurrence in patients receiving intravitreal bevacizumab (gray) ranged from
0% to 10%.
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birthweight as a common risk factor for APROP recurrence
and retreatment. Feng et al33 also noted that the rate of
recurrence was signiﬁcantly higher in patients with zone I
ROP (61%, 101 of 164 eyes) than in zone II ROP (31%, 144
of 465 eyes). Another study of 283 eyes with type 1 ROP also
showed recurrence rates in zone I ROP (58%) were higher
than that in zone II (35.4%).32 The higher rates of recurrence
in zone I ROP compared to zone II ROP may be because
more time is needed to achieve full vascularization, which
may increase the likelihood of subsequent rises on VEGF
levels.
In the original BEAT-ROP study, time to recurrence
was 19.2 weeks after intravitreal bevacizumab compared
with 6.4 weeks after laser treatment for zone I disease.5 In
comparison to recurrence after treatment with intravitreal
bevacizumab, recurrence after treatment with intravitreal
ranibizumab has been observed to occur earlier.25,28,33
Gunay et al25 showed, in 264 eyes with type 1 ROP,
recurrence after treatment with ranibizumab occurred at a
mean interval of 8.75±1.5 weeks compared to 14±2.65
weeks with bevacizumab. In 629 eyes with ROP treated
with ranibizumab, Feng et al33 reported recurrence after
initial treatment occurred at a mean interval of 8.57±3.73
weeks (range: 4–29 weeks).
The higher frequency of recurrence after ranibizumab
may be related to its shorter half-life and is an important
consideration when balancing ranibizumab’s shorter duration of systemic VEGF level suppression with its need for
frequent follow-up and potential retreatment.

Current trials: RAINBOW
The phase III multicenter trial, RAnibizumab Compared With
Laser Therapy for the Treatment of INfants BOrn Prematurely
With Retinopathy of Prematurity (RAINBOW), has closed
recruitment and will evaluate the efﬁcacy and safety of ranibizumab compared with laser therapy in infants with ROP. To
date, the RAINBOW trial (information available at: https://
clinicaltrials.gov/ct2/show/NCT02375971) is the ﬁrst reported
randomized clinical trial to evaluate the potential use of ranibizumab in ROP. Inclusion criteria for the study were 1)
preterm infants with birth weight <1500 grams and 2) bilateral
ROP with one of the following retinal ﬁndings in each eye:
Zone I, stage 1+, 2+, 3, or 3+ disease; zone II, stage 3+ disease;
or APROP. 225 preterm infants were enrolled and randomized
1:1:1 to receive in both eyes either intravitreal ranibizumab 0.2
mg, intravitreal ranibizumab 0.1 mg, or laser photocoagulation
therapy. The primary outcome measure was the percentage of
patients with absence of active ROP at 24 weeks, no
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intervention with a second modality for ROP (treatment
switch) until 24 weeks, and absence of unfavorable structural
outcomes in both eyes at or before 24 weeks. Unfavorable
structural outcomes included retrolental membrane, substantial temporal retinal vessel dragging/macular ectopia posterior
retinal fold involving the macula, and retinal detachment
involving the macula. Limitations of this study include a
large number of sites with low recruitment per site, and
many international sites with a large proportion of Asian
patients.
In addition, the RAINBOW trial had a variety of secondary
outcomes to assess the potential systemic effects of ranibizumab in this study population. In particular, the mean change in
serum ranibizumab concentration and mean change in serum
VEGF levels were assessed at pre-speciﬁed time intervals
before and after treatment. Furthermore, neurodevelopmental
vital signs including body length, weight, blood pressure, head
circumference, and knee to heel length were collected at prespeciﬁed time points in the study. Long-term safety and efﬁcacy data will be collected until participants are 5 years of age,
and will be investigated in the RAINBOW Extension study.

Summary
With the advancement of neonatal care to save more premature infants, particularly those with earlier gestational
age and lower birthweights, ROP continues to be a signiﬁcant cause of visual morbidity worldwide. Laser photocoagulation has been the previous standard of care for
treatment-requiring ROP; however, intravitreal antiVEGF therapy is now another treatment option with
increasing evidence supporting its use. Anti-VEGF therapy has proven effective in inducing acute regression of
ROP, but concerns regarding safety, dosing, and recurrence
remain. Ranibizumab is of particular interest because its
vitreous half-life approaches that of bevacizumab, but after
reaching systemic circulation, the elimination half-life is a
few hours rather than weeks potentially resulting in a less
effect on serum VEGF levels. Although this could be a
distinct advantage for the treatment of ROP, continued
research, including the results of the RAINBOW randomized control trial, are needed to determine the optimal
dose of ranibizumab in ROP, recurrence rate and timing
with need for retreatment, long-term ocular outcomes, and
long-term systemic side effects.
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